Search

Displaying results 231 - 240 of 3917 in total
  1. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    [T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension.

  2. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. … Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).

  3. Drug

    Dexketoprofen

    go.drugbank.com/drugs/DB09214
    ApprovedInvestigationalWithdrawn

    Dexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  4. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    To construct a "living" alternative, a dermal substitute based on collagen I gel was created with mesenchymal cells such as fibroblasts. … The defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts.

  5. Drug

    Dicyclomine

    go.drugbank.com/drugs/DB00804
    ApprovedInvestigational

    [L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967] … [A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.

  6. Drug

    Risedronic acid

    go.drugbank.com/drugs/DB00884
    ApprovedInvestigational

    It functions by preventing resorption of bone[FDA Label][A959].

    Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone Diseases
  7. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    [A193272,A193275,L12648] Avastin was subsequently approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. … EU/UK), the first ophthalmic formulation of bevacizumab developed specifically for intravitreal injection, which received European Commission and MHRA marketing authorization in 2024 and FDA approval on

  8. Drug

    Mepolizumab

    go.drugbank.com/drugs/DB06612
    ApprovedInvestigational

    This indication was subsequently expanded to cover EGPA on December 12, 2017, and HES on September 25, 2020.[L16518] … Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.

  9. Drug

    Guaifenesin

    go.drugbank.com/drugs/DB00874
    ApprovedInvestigationalVet approved

    Regardless, on March 1, 2007, the FDA received a petition asking the FDA to notify the public that some antitussives, expectorants, decongestants, antihistamines, and cough/cold combinations are not known … Since that time the agent has been a combination component of various prescription and non-prescription over-the-counter cough and cold products and is currently a widely available over-the-counter generic

    Mixtures: Doc in the Box All Day Supply, Ed Bron GpProducts: Tussin Non Drowsy, Tussin Adults Non Drowsy
  10. Drug

    Edetate calcium disodium anhydrous

    go.drugbank.com/drugs/DB14598
    ApprovedInvestigational

    [L12774] It is on the World Health Organization Model List of Essential Medicines.[A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774] … Edetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body.